Global News

Quintiles closes Novella Clinical acquisition

Monday, September 23, 2013 01:40 PM

Global CRO Quintiles has completed its previously announced acquisition of Novella Clinical, a full-service CRO focused primarily on emerging oncology as well as medical devices and diagnostics.

More... »

H3 Biomedicine, Selvita collaborate

Monday, September 23, 2013 01:39 PM

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical company specializing in  discovering and developing precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and feasibility of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

Catalent, Supernus partner for supply of Trokendi XR

Monday, September 23, 2013 01:38 PM

Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, and Supernus Pharmaceuticals have entered into an agreement by which Catalent is the supplier of Trokendi XRTM extended release capsules for Supernus.

More... »

Ablynx, AbbVie enter global license agreement for inflammatory diseases

Monday, September 23, 2013 01:37 PM

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, and AbbVie have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

More... »

ClinTec International a finalist in SCRIP 2013 ‘Best CRO’ award

Monday, September 23, 2013 01:34 PM

Global CRO ClinTec International is a finalist for “Best CRO” at the SCRIP Awards 2013, to be held in London’s Lancaster Hotel Nov. 21.

More... »

KaloBios publishes KB001 phase I study results

Monday, September 23, 2013 01:33 PM

KaloBios Pharmaceuticals has published phase I study results for KB001, a first-generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody for use in patients with cystic fibrosis (CF). Data from this initial single-dose clinical study support the continuation of KaloBios' ongoing phase II study of KB001-A, a second-generation, anti-TTSS antibody in CF patients with chronic Pa infections.

More... »

Trifecta Clinical, SAFE-BioPharma partner

Friday, September 20, 2013 10:37 AM

Trifecta Clinical, a global clinical technology solutions provider, has partnered with SAFE-BioPharma to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.

More... »

TrialReach launches new platform giving patients greater access to clinical trials

Friday, September 20, 2013 09:51 AM

TrialReach, a London-based web site that connects patients to clinical trials worldwide, has launched a new platform that dramatically reduces the time and costs required to find clinical trial participants.

More... »

BBK Worldwide forms regional ‘hub’ leaders for its Patient Recruitment Global Alliance

Friday, September 20, 2013 09:47 AM

Established more than a decade ago as a think tank for global enrollment strategies, the BBK Worldwide Patient Recruitment Global Alliance has grown to represent more than 50 companies around the world. These companies work in collaboration to support clinical trial recruitment and retention. Alliance founder BBK now has announced the creation of regional hub leaders to further enhance its ability to evaluate and train international consulting companies in the marketing discipline of patient recruitment, a necessary step to ensure culturally relevant and seamlessly integrated global offerings.

More... »

iCTRS, ViS Research partner for more efficient site selection process

Wednesday, September 18, 2013 03:29 PM

inVentiv Clinical Trial Recruitment Solutions (iCTRS), offering solutions to overcome the costly obstacles that delay clinical trials, has partnered with ViS Research, an online feasibility platform using interactive visualizations, to revolutionize and speed the antiquated system of clinical trial site evaluation.

More... »